Elliot Maza served as Interim and then Chief Executive Officer of Immune Pharmaceuticals, Inc. from May 2017 until August 2018, after serving as a Director since January 2015.
Elliot Maza executed the "Reverse-merger" transaction in lieu of IPO and prepared SEC filings and managed all stock market-related transactions. He was also responsible for drafting all press releases and coordinated investor awareness programs.
Elliot Maza is a registered attorney and a licensed C.P.A. (inactive) in the states of New York and New Jersey. He received a Bachelor of Science in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.
Elliot Maza worked at Immune Pharmaceuticals Inc. for a year as Chief Executive Officer and Principal Financial Officer.
While working there, he served as Board member, interim CEO and then President, CEO and Principal Financial Officer of clinical-stage, Biopharmaceutical Company developing therapeutic agents for the treatment of immunologic and inflammatory diseases, including dermatological and gastroenterological conditions.
YOU ARE READING
Elliot Maza - Fort Lee, New Jersey
RandomPresident at Intellect Neurosciences, Inc. | Business Officer and Co-Founder at Various Life Science Companies
